RxDoctor Payments Data

Sherry Reid, MD

Neurology · Decatur, ILNPI 1104835412

Payments from drug & device makers

$7,992in general payments, 2019–2025

Across 440 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$837
  • Biohaven Pharmaceuticals, Inc.$451
  • Livanova USA, Inc.$397
  • Supernus Pharmaceuticals, Inc.$371
  • Pfizer$332
  • plus $4K from 36 others

What the payments were for

  • Speaking & faculty fees$160%
  • Food & beverage$6,98687%
  • Education$99012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,992 in reported general payments places this provider in the 70th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$310,531
Medicare patients
486
Services billed
23,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5018$154,080
AptiomEslicarbazepine Acetate27$49,529
BriviactBrivaracetam22$39,497
Nurtec OdtRimegepant Sulfate26$39,492
QuliptaAtogepant21$22,523
UbrelvyUbrogepant15$21,725
FycompaPerampanel12$16,879
XcopriCenobamate12$16,309
Aimovig AutoinjectorErenumab-Aooe19$13,867
Memantine Hcl ErMemantine Hcl135$8,056
Emgality PenGalcanezumab-Gnlm12$8,047
Divalproex Sodium14$3,615
Galantamine ErGalantamine Hbr53$3,588
Carbidopa-LevodopaCarbidopa/Levodopa172$3,575
Rivastigmine21$2,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$196$154,08018 claims
Sunovion Pharmaceuticals Inc.Aptiom$244$49,52927 claims
AbbVieQulipta, Ubrelvy$1,857$44,24736 claims
UCB, Inc.Briviact$303$39,49722 claims
PfizerNurtec Odt$332$39,49226 claims
Eisai Inc.Fycompa$85$16,87912 claims
SK Life Science, Inc.Xcopri$46$16,30912 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$81$84815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 790 neurology providers in Illinois.

Other neurology in Decatur

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →